A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer

NCT05328908 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

770

Enrollment

INDUSTRY

Sponsor class

Stopped Inability to meet protocol objectives

Conditions

Colorectal Neoplasms

Interventions

DRUG: Nivolumab-relatlimab FDC
DRUG: Regorafenib
DRUG: TAS-102

Sponsor

Bristol-Myers Squibb